142 related articles for article (PubMed ID: 9654335)
1. Transient expression of the vesicular monoamine transporter during development in the rat thalamus and cortex.
Leroux-Nicollet I; Costentin J
Neurosci Lett; 1998 Jun; 248(3):167-70. PubMed ID: 9654335
[TBL] [Abstract][Full Text] [Related]
2. Regulation of rat brain vesicular monoamine transporter by chronic treatment with ovarian hormones.
Rehavi M; Goldin M; Roz N; Weizman A
Brain Res Mol Brain Res; 1998 Jun; 57(1):31-7. PubMed ID: 9630494
[TBL] [Abstract][Full Text] [Related]
3. Decreased limbic vesicular monoamine transporter 2 in a genetic rat model of depression.
Schwartz K; Yadid G; Weizman A; Rehavi M
Brain Res; 2003 Mar; 965(1-2):174-9. PubMed ID: 12591135
[TBL] [Abstract][Full Text] [Related]
4. Characterization of high-affinity [3H]TBZOH binding to the human platelet vesicular monoamine transporter.
Zucker M; Weizman A; Rehavi M
Life Sci; 2001 Sep; 69(19):2311-7. PubMed ID: 11669473
[TBL] [Abstract][Full Text] [Related]
5. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice.
Kilbourn MR; Kuszpit K; Sherman P
Synapse; 2000 Mar; 35(4):250-5. PubMed ID: 10657034
[TBL] [Abstract][Full Text] [Related]
6. In vivo imaging of the brain vesicular monoamine transporter.
Vander Borght TM; Kilbourn MR; Koeppe RA; DaSilva JN; Carey JE; Kuhl DE; Frey KA
J Nucl Med; 1995 Dec; 36(12):2252-60. PubMed ID: 8523116
[TBL] [Abstract][Full Text] [Related]
7. Binding of alpha-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific.
Kilbourn M; Lee L; Vander Borght T; Jewett D; Frey K
Eur J Pharmacol; 1995 May; 278(3):249-52. PubMed ID: 7589162
[TBL] [Abstract][Full Text] [Related]
8. Transient developmental expression of monoamine transporters in the rodent forebrain.
Lebrand C; Cases O; Wehrlé R; Blakely RD; Edwards RH; Gaspar P
J Comp Neurol; 1998 Nov; 401(4):506-24. PubMed ID: 9826275
[TBL] [Abstract][Full Text] [Related]
9. Reserpine affects differentially the density of the vesicular monoamine transporter and dihydrotetrabenazine binding sites.
Naudon L; Raisman-Vozari R; Edwards RH; Leroux-Nicollet I; Peter D; Liu Y; Costentin J
Eur J Neurosci; 1996 Apr; 8(4):842-6. PubMed ID: 9081637
[TBL] [Abstract][Full Text] [Related]
10. Reserpine or chronic paroxetine treatments do not modify the vesicular monoamine transporter 2 expression in serotonin-containing regions of the rat brain.
Vilpoux C; Leroux-Nicollet I; Naudon L; Raisman-Vozari R; Costentin J
Neuropharmacology; 2000 Apr; 39(6):1075-82. PubMed ID: 10727718
[TBL] [Abstract][Full Text] [Related]
11. Vesicular monoamine transporter-2: immunogold localization in striatal axons and terminals.
Nirenberg MJ; Chan J; Liu Y; Edwards RH; Pickel VM
Synapse; 1997 Jun; 26(2):194-8. PubMed ID: 9131778
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the subregional distributions of the monoamine vesicular transporter and dopamine uptake complex in the rat striatum and changes during aging.
Leroux-Nicollet I; Costentin J
J Neural Transm Gen Sect; 1994; 97(2):93-106. PubMed ID: 7873127
[TBL] [Abstract][Full Text] [Related]
13. In vivo binding of (+)-alpha-[3H]dihydrotetrabenazine to the vesicular monoamine transporter of rat brain: bolus vs. equilibrium studies.
Kilbourn M; Sherman P
Eur J Pharmacol; 1997 Jul; 331(2-3):161-8. PubMed ID: 9274975
[TBL] [Abstract][Full Text] [Related]
14. Ontogeny of vesicular monoamine transporter mRNAs VMAT1 and VMAT2. I. The developing rat central nervous system.
Hansson SR; Hoffman BJ; Mezey E
Brain Res Dev Brain Res; 1998 Sep; 110(1):135-58. PubMed ID: 9733951
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of scopolamine on in vivo binding of dopamine transporter and vesicular monoamine transporter radioligands in rat brain.
Kilbourn MR; Kemmerer ES; Desmond TJ; Sherman PS; Frey KA
Exp Neurol; 2004 Aug; 188(2):387-90. PubMed ID: 15246838
[TBL] [Abstract][Full Text] [Related]
16. Amino- and amido-tetrabenazine derivatives: synthesis and evaluation as potential ligands for the vesicular monoamine transporter.
Canney DJ; Kung MP; Kung HF
Nucl Med Biol; 1995 May; 22(4):527-35. PubMed ID: 7550031
[TBL] [Abstract][Full Text] [Related]
17. Lobeline displaces [3H]dihydrotetrabenazine binding and releases [3H]dopamine from rat striatal synaptic vesicles: comparison with d-amphetamine.
Teng L; Crooks PA; Dwoskin LP
J Neurochem; 1998 Jul; 71(1):258-65. PubMed ID: 9648873
[TBL] [Abstract][Full Text] [Related]
18. Elevated platelet vesicular monoamine transporter density in untreated patients diagnosed with major depression.
Zucker M; Aviv A; Shelef A; Weizman A; Rehavi M
Psychiatry Res; 2002 Nov; 112(3):251-6. PubMed ID: 12450634
[TBL] [Abstract][Full Text] [Related]
19. Chronic clozapine, but not haloperidol, treatment affects rat brain vesicular monoamine transporter 2.
Rehavi M; Roz N; Weizman A
Eur Neuropsychopharmacol; 2002 Jun; 12(3):261-8. PubMed ID: 12007678
[TBL] [Abstract][Full Text] [Related]
20. In vivo measures of dopaminergic radioligands in the rat brain: equilibrium infusion studies.
Kilbourn MR; Sherman PS; Kuszpit K
Synapse; 2002 Mar; 43(3):188-94. PubMed ID: 11793424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
